Sweden's Orexo Q2 revenue falls, net loss widens on higher operating expenses
Sweden's Orexo Q2 revenue falls, net loss widens on higher operating expenses
Overview
Sweden specialty pharma firm's Q2 revenue fell yr/yr, net loss widened
Earnings per share before and after dilution for Q2 was SEK -2.92, reflecting ongoing R&D investment
Company advanced rescue medication pipeline and saw increased interest in AmorphOX technology
Outlook
Orexo expects to start pivotal OX640 trial in Q4 2026, with read-out in Q1 2027
Company plans Izipry NDA resubmission in Q3 2026, potential FDA approval in Q1 2027
Orexo is evaluating opportunities for additional financing to support growth and resolve DOJ-related legal matters
Result Drivers
OPERATING EXPENSES - Higher operating expenses reflected continued R&D and organizational adaptation after Zubsolv US divestment
PARTNERING INTEREST - Co reported increased external interest and multiple partnering discussions for AmorphOX technology
Company press release: ID:nMFN15mCdr
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | SEK 3.50 mln | SEK 5 mln (1 Analyst) |
Q2 Adjusted EPS |
| -SEK 2.92 |
|
Q2 EPS |
| -SEK 2.92 |
|
Q2 EBIT |
| -SEK 103.30 mln |
|
Q2 EBITDA |
| -SEK 95.10 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Orexo AB is SEK39.50, about 83.7% above its July 15 closing price of SEK21.50
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)